Sana Biotechnology, Inc. (SANA)
NASDAQ: SANA · IEX Real-Time Price · USD
10.44
+0.66 (6.75%)
At close: May 3, 2024, 4:00 PM
10.49
+0.05 (0.44%)
After-hours: May 3, 2024, 6:39 PM EDT
Sana Biotechnology Employees
Sana Biotechnology had 328 employees on December 31, 2023. The number of employees decreased by 93 or -22.09% compared to the previous year.
Employees
328
Change (1Y)
-93
Growth (1Y)
-22.09%
Revenue / Employee
n/a
Profits / Employee
-$863,582
Market Cap
2.31B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 328 | -93 | -22.09% |
Dec 31, 2022 | 421 | 38 | 9.92% |
Dec 31, 2021 | 383 | 118 | 44.53% |
Dec 31, 2020 | 265 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Patterson Companies | 7,600 |
Guardant Health | 1,779 |
Twist Bioscience | 919 |
Intellia Therapeutics | 526 |
RxSight | 374 |
Vericel | 314 |
Kymera Therapeutics | 187 |
Geron | 141 |
SANA News
- 12 days ago - Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX - Invezz
- 2 months ago - Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates - GlobeNewsWire
- 2 months ago - Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP - GlobeNewsWire
- 2 months ago - Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 3 months ago - Sana Biotechnology Announces Pricing of Upsized Public Offering - GlobeNewsWire
- 3 months ago - Sana Biotechnology Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 4 months ago - Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies - GlobeNewsWire